Intuitive Surgical - A 60%+ Market Share That Comes with 85% Recurring Revenue (A Deep Dive)
Exploring the numbers, moat, business model, and growth engine behind the global leader in robotic surgery.
Intuitive Surgical has quietly become one of the most important companies in modern healthcare. Over the past three decades, it has transformed how complex surgeries are performed, pioneering robotic-assisted procedures that are safer, more precise, and less invasive. Its da Vinci system is now the global standard in surgical robotics, used in millions of operations each year across more than 70 countries.
No, this isn’t just another medtech manufacturer; Intuitive has built an entire surgical ecosystem. Hospitals design workflows around their systems, surgeons are trained on their platforms, and their installed base drives years of high-margin, recurring revenue through instruments, accessories, and service contracts. With over 11,000 systems in use and an estimated 60%+ share of the robotic surgery market, the company’s dominance is difficult to overstate.
For investors, Intuitive combines the financial profile of a high-quality compounder with the resilience of a mission-critical healthcare provider. Roughly 85% of its $10 billion in annual revenue now comes from recurring sources; revenue has grown at a 15% CAGR over the past decade; gross margins are near 70%; and it produces over $1 billion in annual free cash flow with virtually no debt.
Furthermore, its razor-and-blade model, where each new system drives years of recurring revenue, provides remarkable visibility, while secular tailwinds from the global shift toward minimally invasive care continue to expand its addressable market.
Few businesses combine innovation, profitability, and durability at this scale, making Intuitive a rare long-term compounder in the medtech space.
In this Deep Dive, I’ll break down everything you need to know about Intuitive Surgical, from its da Vinci ecosystem and competitive moat to its financial performance, growth runway, and valuation, and explore whether this surgical innovator remains a must-own or a brilliant business trading at too full a price.
In other words, is it worth owning, and is now the right time to buy?
Welcome to InvestInsights — an independent equity research publication rooted in long-term, buy-and-hold investing, publishing actionable stock/equity research reports weekly!
📈 You’re reading my latest [FREE] stock analysis. If you like this analysis, make sure to like & subscribe to receive much more like this!
If you’d like full portfolio access (14% CAGR since 2022) & additional exclusive reports, consider becoming a paid subscriber!
Intuitive Surgical – everything you need to know!
Business fundamentals
Delving right in, Intuitive is one of the most innovative and leading-edge companies in the healthcare industry, or, more specifically, in next-generation surgical equipment, truly changing the way complex operations are performed and redefining what is possible with minimally invasive surgery.
Let me tell you all you need to know about this innovator!
Founded in 1995 and headquartered in Sunnyvale, California, Intuitive Surgical is a medical technology company that develops, manufactures, and markets robotic-assisted surgical systems. It combines advanced robotics, high-definition 3D visualization, and sophisticated instruments to enhance a surgeon’s precision, dexterity, and control, enabling them to perform complex operations through small incisions, thereby making procedures less invasive and more precise.
Over nearly three decades, Intuitive has transformed the way many soft-tissue surgeries are performed. Its systems are now used across a broad range of specialties, from urology and gynecology to general and thoracic surgery, and have become the standard in several high-volume procedures such as prostatectomy and hysterectomy. Hospitals adopt the technology to reduce complications, shorten patient recovery times, and market their surgical capabilities, while surgeons value the ergonomics and precision that the robotic interface provides.
As a result, the company now employs over 16,000 people, has a market capitalization of $160 billion, generates nearly $10 billion in annual revenue, and has an installed base of over 11,000 robotic systems across 74 countries, which have already performed more than 17 million surgical procedures.
This isn’t just any company, but the dominant force in robotic surgery technologies, capturing an estimated 60% market share globally.
And it’s all about a single platform/product – The Da Vinci Surgical System.
While the company now sells a few complementary technologies, like Ion (a robotic-assisted bronchoscopy system for lung biopsy) and some accessories/digital tools, almost all of Intuitive’s revenues are tied to the Da Vinci line, which has positioned it at the center of one of the fastest-growing healthcare markets, with 2.7 million surgeries performed using the Da Vinci platform in 2024 alone.
So, what is the Da Vinci medical system, and how has it propelled Intuitive to the #1 position in robotic surgery equipment?
The da Vinci Surgical System is Intuitive Surgical’s flagship robotic-assisted platform. It was created to help surgeons perform complex procedures through small incisions with far greater precision, dexterity, and visualization than traditional laparoscopy allows.
At its core, the system translates a surgeon’s hand movements at a console into finely controlled motions of wristed robotic instruments inside the patient while providing a high-definition, three-dimensional view of the operative field. This combination of natural hand control, tremor filtration, and immersive imaging makes technically demanding operations safer, more efficient, and less physically taxing for surgeons.
The result? Reduced blood loss during operation, shorter hospital stays, quicker recovery, and a large body of clinical studies showing non-inferior or superior outcomes to laparoscopy in many procedures.
Since its first FDA clearance in 2000, da Vinci has gone through several major generations that steadily improved its capabilities and broadened its appeal. Early Standard, S, and Si systems enhanced ergonomics and visualization; the Xi platform, launched in 2014, introduced multi-quadrant access, slimmer arms, and flexible port placement, becoming the workhorse for general surgery.
The lower-cost X model followed in 2017 to help cost-conscious hospitals enter robotics, while the SP (single-port) system, cleared in 2018, enabled narrow access procedures such as urology and certain head-and-neck operations. In 2024, Intuitive launched da Vinci 5, its most advanced version to date, adding enhanced force feedback, improved imaging and computing power, and digital integration for training and performance analytics.
However, what truly propelled Intuitive to the #1 position in surgical robotics is not just the hardware but the ecosystem it built around the system. Intuitive moved early to secure regulatory approvals and generate clinical evidence in high-volume specialties such as urology and gynecology. As prostate and hysterectomy cases proved the safety and efficiency of robotic surgery, hospitals invested in systems, surgeons trained on da Vinci during residency, and payers became comfortable reimbursing the procedures. This created a powerful feedback loop: more cases justified more system purchases, which produced more data, more trained surgeons, and deeper institutional know-how.
Furthermore, once a hospital trains staff, integrates workflows, and signs long-term service contracts, switching becomes costly and disruptive.
Meanwhile, Intuitive continues to rapidly innovate on its solid base. Take digital collaboration capabilities, or telesurgery, which the company has been developing since 2009. Today, with the aid of intuitive equipment, surgeries can be performed with the patient and surgeon separated by oceans.
“Last week, at the Society of Robotic Surgery Conference, Doug Stoddard, Director of Surgery and Robotics at Christus Health; and Dr. Andrea Pakula, Medical Director of Robotic Surgery at Adventist Health, performed a telesurgery demonstration between Atlanta and Strasberg on an advanced tissue model using da Vinci 5, including force feedback.”
The opportunity here is massive.
Anyway, put simply, da Vinci changed what was surgically possible, became the training and clinical standard as minimally invasive surgery accelerated, and then solidified its lead with an ecosystem of training, consumables, services, and continuous innovation. That combination of technology and network effects is why Intuitive remains the clear global leader in robotic-assisted surgery today.
So, da Vinci is a fantastic platform, but also Intuitive’s primary source of revenue. It’s estimated to drive about 90% of sales today, with newer technologies such as Ion making up the rest.
That concentration means a disruptive technology, major safety issue, or regulatory setback could hit both new system sales and the lucrative recurring stream from instruments and services. A recall or a shift toward a cheaper, clinically validated alternative would hurt the top line.
Yet this risk is less fragile than it seems. Da Vinci isn’t a single static product but a continually evolving platform with multiple generations that add new capabilities and procedures, deepening hospitals’ training, workflows, and service ties. Its razor-and-blade model further locks in customers: surgeons are trained on da Vinci, payers recognize its outcomes, and switching would mean retraining and workflow disruption.
Meanwhile, Intuitive is working to diversify. New systems like Ion are growing fast, and the company is investing in flexible robotics, advanced imaging, AI guidance, and telepresence. These aren’t big enough yet to shift the revenue mix, but they signal a clear strategy to broaden beyond soft-tissue robotics.
All told, revenue concentration is a real risk but not a deal-breaker given da Vinci’s deep entrenchment and Intuitive’s ongoing innovation.
With that established, the next big question is: How does Intuitive generate revenue?
Let me point out right away that Intuitive has one of the highest-quality and most compelling revenue streams you’ll find, as it extends well beyond just medical system sales.
In fact, today the company generates just 15% of its revenue from system sales, with 85% coming from recurring revenue sources, a model very similar to Thermo Fisher Scientific.
Ultimately, the company generates revenue through a combination of system sales, recurring instruments and accessories usage, and service contracts, creating a durable, high-margin business model.
The company’s model is deliberately “razor-and-blade,” with most revenue coming after installation, through service contracts (maintenance and support) and recurring instrument purchases (single-use or limited-use surgical instruments and drapes used with each procedure).
Initially, Intuitive earns money through the sale of its systems. A system typically costs between $500,000 and $2 million, depending on its configuration.
Following the initial sale, the company derives most of its revenue from instruments and accessories. Each da Vinci procedure requires specialized, single-use or limited-use tools (scissors, graspers, staplers, energy devices, and drapes) that must be replaced after a set number of uses. As surgeons perform more operations, hospitals continuously purchase these consumables, providing Intuitive with a powerful recurring revenue stream, entirely driven by system usage.
Since hospitals typically retain these systems for 7-10 years, the flywheel effect is remarkable - each system sale is then followed by 7-10 years of high-margin, recurring revenue from consumables.
Thirdly, there are service contracts. Once a hospital installs a system, it usually signs a multiyear maintenance agreement for software updates, repairs, and preventive service. These contracts provide a steady, high-margin revenue base and deepen the relationship between Intuitive and its customers.
This entire model gives Intuitive a powerful mix: large upfront sales when new systems are installed and a high-margin, predictable recurring stream tied to each additional procedure performed on its installed base, which makes it a very reliable performer.
Ultimately, Intuitive is just a brilliant business and an undisputed leader in a highly promising healthcare market.
Today, the da Vinci installed base continues to grow rapidly, as procedure volumes have increased steadily as surgeons adopt minimally invasive techniques and hospitals seek to improve patient outcomes and operating room efficiency.
With a strong first-mover advantage, a deep ecosystem of trained surgeons, and a focus on clinical evidence and long-term innovation, Intuitive Surgical has established itself as the clear leader in robotic-assisted surgery, continuing to benefit from the growing demand for less invasive surgical care worldwide.
In soft-tissue robotic surgery, some estimates put its market share at over 70% and toward 80% globally, while broader surgical equipment market estimates put its share at around 60%, well ahead of second-place Stryker Corporation (15%).
This gives it a near-monopolistic position, or what is often referred to as a quasi-monopoly.
Does Intuitive Surgical have a moat? + emerging competition
To answer this question right away: Intuitive has one of the widest and most durable moats in medical technology, built around its da Vinci robotic surgery ecosystem.
Its advantage starts with an installed base of over 11,000 systems worldwide. Hospitals that own da Vinci robots have built operating room layouts, service contracts, supply chains, and capital budgets around them, making a switch highly unlikely.
Added to this is surgeon training lock-in: most robotic surgeons first learn on da Vinci during residency or fellowship, and moving to another platform means new credentialing, retraining OR teams, and workflow disruption. This self-reinforcing loop keeps new surgeons inside the ecosystem and makes displacement slow.
Intuitive also enjoys a regulatory and payer head start. Decades of clinical data and broad approvals underpin reimbursement frameworks built with da Vinci outcomes in mind. At the same time, new entrants must prove safety and efficacy and win payer acceptance country by country, a process that takes years.
Its continuous innovation further deepens loyalty: each new generation (Si, Xi, SP, and now da Vinci 5) adds features like better imaging and force feedback without forcing surgeons to relearn. Hospitals tend to upgrade rather than switch. Finally, the brand trust built over millions of procedures makes “robotic surgery” almost synonymous with “da Vinci,” a significant advantage in a safety-critical, risk-averse industry.
Taken together, Intuitive has a formidable moat that protects its dominance in soft-tissue robotics.
Yet it is not invincible. As in any attractive market, competition is rising. New platforms are targeting cost-sensitive regions and hospitals that want more flexible or lower-priced systems. Medtronic’s Hugo and CMR Surgical’s Versius are the most visible: Versius has surpassed 30,000 global procedures and recently gained U.S. clearance, while Hugo is rolling out internationally with modular arms and an “open console” aimed at ergonomics and easier OR communication. Johnson & Johnson’s Ottava is on the horizon, and other device makers, including Smith & Nephew and Stryker, are expanding into robotics.
These challengers bring real differentiators - modularity, smaller footprint, improved ergonomics, and lower upfront or per-procedure cost - that could nibble at Intuitive’s share where budgets are tight or training lock-in is weaker. There is also the risk of pricing pressure, including from remanufactured instruments; Deutsche Bank, for example, projects they could cut U.S. instrument sales for Intuitive by 10–15 % by 2028.
In short, Intuitive’s moat is very strong but not unassailable. Competition is intensifying, and while any share loss is likely to be gradual, investors should watch for signs of erosion or margin pressure as rivals scale.
Industry growth dynamics
The surgical robotics industry is evolving rapidly, driven by a clear shift toward minimally invasive procedures and the growing recognition that robots can enhance surgical precision, safety, and consistency. Robotic systems outperform human hands in stability and dexterity, enabling fine, controlled movements in three dimensions and providing surgeons with magnified, high-definition, 3D visualization of the operative field. They also enhance surgeon ergonomics by allowing the operations to be performed from a seated console, thereby reducing fatigue and facilitating more consistent outcomes.
It should therefore come as no surprise that this is a rapidly growing market – one of the most compelling in healthcare for the next few decades.
Looking at research firm forecasts for the robotic surgical market, these point to a low-teens (11% to 14%) CAGR through the early 2030s, driven by several structural tailwinds: rising adoption of minimally invasive techniques; ongoing advances in imaging, AI, and automation; expansion into new specialties such as thoracic, colorectal, and bariatric surgery; an aging global population; and hospital incentives to improve efficiency and reduce complications.
Falling system costs and more modular designs are also opening the market to smaller hospitals and emerging economies.
Most importantly, these are trends that aren’t going anywhere and which will likely last for decades to come, providing their leading players with a massively compelling long-term outlook.
For Intuitive Surgical, these dynamics suggest a continued tailwind for growth, even as competition intensifies. System placements may moderate in mature segments, but expanding procedure volumes, new specialties, and rising adoption in emerging markets should support low double-digit to mid-teens growth in the years ahead, even when we assume some market share erosion, also supported by a massive stalled base which continues to bring in a strong recurring revenue stream, which only continues to grow as procedure frequency increases.
In other words, Intuitive’s medium-term outlook remains sublime, while there is also a clear runway for growth in the 2030s.
With that, I think we have a pretty good understanding of this business and its underlying dynamics. So, let’s move on to financials and recent performance!
A Financial & Performance Review
Intuitive has been compounding its financials at an impressive rate in recent years.
If we take the last decade, the company has grown revenues at an impressive 15% CAGR, and it has done so with incredible consistency. For reference, the company has delivered just two quarters of negative YoY growth over the last 10 years, both of which occurred during the first year of COVID. If we exclude 2020, Intuitive didn’t report a single quarter of negative growth and only 5 quarters (out of 40) where YoY growth fell below 10%.
That is massively impressive.
Driving this incredible growth for Intuitive over the last decade has been a combination of rising procedure volumes (due to growing adoption of robotics and demand for minimally invasive procedures), geographic and specialty expansion, product upgrades (due to newer generations), and the power of its recurring revenue model (more procedures mean more consumables sales). It is less about a single breakthrough and more about a carefully managed ecosystem that continues to expand.
These growth drivers are no different today.
Shifting our focus to more recent times (which is arguably a bit more relevant), let’s assess its latest financial report.
Intuitive released its latest financial results back in late July and once again delivered strong results across the board, surpassing consensus estimates, even as the business is dealing with the effects of international macro weakness and tariff-driven margin pressure.
Offsetting this were the continued ramp of da Vinci 5, which continues to see strong adoption in the U.S., and the new platform received clearances in Europe and Japan, which allows Intuitive to scale this new line further. Additionally, the company received procedure clearance for tracheal bronchoplasty, a surgical treatment for a collapsed trachea and main bronchi during normal breathing, further growing the number of applications for its surgical platform.
On that note, let’s delve into the reported numbers.
Intuitive placed 395 new systems during Q2, including 180 da Vinci 5 systems, which carry a higher price and therefore provide a substantial boost to revenue growth. In terms of regional placement strength, Intuitive saw a good performance in the U.S., offsetting macro headwinds in Japan, China, and Europe.
Intuitive indicates that it continues to see ongoing financial and budgetary pressures in Japan, China, and Europe, reflecting government budget challenges and uncertainties over the trade environment. Simply put, hospital capex is being held back in these regions, dragging on Intuitive’s performance here, as demand remains pressured.
Nevertheless, system placement was strong in Q2, leading to 14% growth in Intuitive’s installed base to almost 10,500 systems globally. As shown below, the company’s installed base has expanded at a consistent mid-teens pace over the past three and a half years, with growth even accelerating slightly in 2024 and 2025 – a remarkable feat given its already substantial scale.
For now, the powerful tailwinds supporting both Intuitive and the broader robotics industry, including rising adoption, expanding procedural clearances, and growing international acceptance, continue to outweigh the natural headwinds of size and maturity. This sustained momentum underscores the resilience of Intuitive’s business model, the enduring secular forces that drive its long-term growth story, and its growth momentum.
Meanwhile, on top of this healthy installed base expansion, system utilization, defined as procedures per installed clinical system, also grew 2% YoY, as Intuitive robotic systems receive procedure clearance for more applications. Add to this growing overall adoption of robotic surgical systems, and utilization continues to increase.
Ultimately, this combination of installed base expansion and higher utilization led to impressive and resilient growth in procedures of 17% YoY.
Once again, the historical numbers highlighted below look excellent. Driven by the same dynamics and tailwinds just discussed, a combination of a growing installed base and higher utilization has led to outstanding growth in procedure volume, which has stabilized in the mid-to-high teens in 2024 and so far in 2025.
Breaking down procedure growth further, Intuitive reported 14% growth in the U.S., driven by “strength in benign general surgery with notable growth in cholecystectomy and appendectomy,” as reported by management.
In the U.S., there have been concerns about the impacts of fiscal policy on Medicaid recipients, who number approximately 70-80 million Americans and could potentially lose this program coverage. In turn, this could impact procedure volume, as fewer would be able to afford them, potentially dragging on Intuitive’s performance. However, management highlighted that Intuitive’s relative penetration is lower among Medicaid patients than among patients with other types of coverage, and Medicaid patients tend to be younger than the overall population, thereby playing a smaller role in its procedure volume.
In other words, management claims the impact should be limited. However, no actual numbers were disclosed, and I get the sense that management is still somewhat uncertain about the potential implications. By current estimates, I think this could drag on Intuitive’s U.S. growth rate by a few percentage points, though this remains to be seen given minimal visibility. I think it is good to exercise caution regarding this impact in the 2026 financial projections.
Moving abroad, Intuitive continues to see strong growth outside the U.S., with da Vinci procedure volumes growing 23% YoY in Q2, with substantial contributions from India, Korea, and distributor markets. In China, Intuitive saw growth slightly ahead of the global average, though it continues to reflect a constrained and competitive capital environment.
Ultimately, this excellent procedure growth, both in the U.S. and internationally, led to strong revenue growth for Intuitive in Q2, growing 21% YoY to $2.44 billion.
Notably, we can see growth accelerate in 2024 and into 2025, driven by healthy, stable underlying growth dynamics and a more favorable product mix, with strong adoption of the more expensive da Vinci 5 system boosting revenue growth, as highlighted by 28% growth in systems revenue and an average selling price of $1.5 million, up from $1.44 million a year ago.
These dynamics should continue to translate into strong growth in H2 as well, though I expect it to moderate gradually as Intuitive laps the initial ramp-up of da Vinci 5 systems in 2024. Subsequently, growth should normalize into the low-to-mid teens in 2026, as underlying dynamics remain healthy but mix benefits ease.
Apart from 28% growth in systems revenue, it is also worth highlighting that recurring revenue grew strongly by 21% YoY as well, now accounting for 85% of revenue. Growth here was driven by strong procedure volume, a larger installed base, and instrument and accessory revenue per procedure of approximately $1,800, roughly flat YoY.
Ultimately, I am really pleased with Intuitive’s growth dynamics. Despite the company facing mild headwinds, particularly outside of the U.S., its numbers don’t show any weakness, and momentum remains very much intact, which I anticipate continuing in the years ahead – I see no reason to assume otherwise.
Excellent execution and strong secular tailwinds continue to pay off.
On that note, let’s move to the bottom-line result, taking a closer look at margins and cash flows, which were slightly better than management’s expectations.
Intuitive reported a gross margin of 67.9%, down 210 bps YoY. This decline primarily reflects “higher facilities costs, including depreciation related to new manufacturing capacity, a greater mix of lower-margin Ion and da Vinci 5 revenue, and higher service costs related to da Vinci 5,” as quoted from management. While the strong adoption of higher-priced new platforms gave revenue growth a solid boost, amid the early ramp, these products carry lower margins, which dragged on overall product margin, as reflected in the gross margin decline.
Additionally, Intuitive faced a tariff headwind of approximately 60 bps, mainly related to China. Notably, the impact was about 40 bps lower than anticipated, reflecting the reduction in bilateral tariff rates on U.S.-China trade. At the same time, we should expect this headwind to get worse throughout the year, as “tariff expense rolls through inventory into cost of sales.”
Nevertheless, I will call this a healthy Q2 gross margin.
Moving further down the line, it is worth noting that Intuitive continues to invest heavily in R&D to advance its robotic platforms, improve imaging and digital tools, and introduce new instruments and capabilities that support more complex and precise surgery. Last quarter, R&D sat at 13% of revenue, with R&D costs up 12% YoY.
In total, this led to 9% growth in operating expenses in Q2, driven by a higher headcount and increased facility costs, including depreciation, partially offset by lower legal fees. This translated into an operating margin of 30.5%, up 230 bps YoY, thanks to improved operating leverage, with operating expenses growing more slowly than revenue despite continued investments.
As highlighted above, Intuitive has been steadily improving its operating margin, after a dip in late 2022 coming off COVID-related highs, which is a promising sign. Even as Intuitive remains aggressive with its investments, operating leverage continues to improve, in part driven by its razor-and-blade business model.
Simply put, as more da Vinci systems are placed around the world, each one continues to produce ongoing revenue every time it’s used, while Intuitive’s overhead (like R&D, sales, and support) grows much more slowly. This means profit margins expand as the installed base scales, since each new system adds incremental revenue faster than it adds expenses.
This also benefits it all the way down the line, with Intuitive consistently reporting impressive EPS growth, outpacing revenue. In Q2, EPS grew 23% YoY to $2.19.
Finally, let’s highlight FCF, which has fluctuated a bit more in recent years due to COVID-related benefits and higher CapEx to realize facility and capacity expansion. However, we did see a healthy jump in FCF again in 2024, with the FCF margin improving to 16% and FCF once again exceeding $1 billion. I expect this to further improve in 2025 and scale further in the years that follow, driven by improved operating leverage, offsetting continued high capex.
As a result of these healthy cash flows, Intuitive has always maintained a strong balance sheet. The company ended Q2 with $9.5 billion in cash and investments against practically no debt, which is sublime. This is a bulletproof balance sheet, with plenty of liquidity.
All in all, a robust quarter for Intuitive, showing barely any weakness, despite temporary headwinds, with strong growth and healthy, improving margins.
On that note, let’s get to the outlook!
Want more out of your subscription? Even more content like this weekly?
Consider InvestInsights PRO - $7.50/month ($70/annually)
This gets you:
A guaranteed 6+ stock analyses every month (roughly 2-4 paid-exclusive).
Complete insight into my own portfolio, allocation & performance
(14% return CAGR since 2022).
Instant transaction alerts anytime I make a move (Fully transparent).
A complete overview of all my target prices and ratings (online available).
Outlook & Valuation
Starting with the short-term outlook, let’s consider management’s guidance. After a strong Q2, Intuitive management updated its 2025 procedure growth guidance, raising the low end of the range and pointing to growth within 15.5%-17%, suggesting some potential weakening in H2.
The low end of this guidance assumes continued trade headwinds between the U.S. and China, as well as macro headwinds and growing competition. Additionally, this guidance reflects international CapEx budgets to remain constrained, limiting international expansion. Meanwhile, the high end of the range assumes growth in China will improve in H2 and that these international headwinds will ease.
On the revenue side, assuming the midpoint of guidance, I expect H2 growth to moderate toward the mid-to-high teens amid slowing procedure growth and easing mix benefits. For the full year, I expect this to result in revenue growth of 18.2% to $9.87 billion, assuming stable U.S.-China trade, which remains by far the largest uncertainty to Intuitive’s near-term outlook.
Moving to the bottom line, Intuitive guides for a 2025 gross margin of between 66% and 67%, also raised from the prior quarter amid a strong Q2 performance. This suggests a roughly 150 bps YoY decline at the midpoint, reflecting a higher impact from tariffs and significant incremental depreciation on new facilities.
Positively, growth in operating expenses should be mild, with management guiding 2025 growth between 10% and 14%, which should come in below revenue growth, though it points to higher expenses in H2. Furthermore, this improved leverage should offset some of the decline in gross margin. However, I expect the operating and net income margins to face some pressure in 2025 due to these temporary cost headwinds and continued investments.
As a result, I expect a pressured EPS performance, as reflected in my projection below for “only” 12% EPS growth.
Looking further ahead, based on everything discussed so far, I expect growth to moderate further in 2026 and remain fairly stable in the mid-teens range through 2028, driven by strong growth in procedures and consumables, supported by a growing installed base. The assumptions below assume continued trade headwinds and some market share erosion due to increased competition.
On the bottom line, I expect margin headwinds to persist in 2026 due to continued tariff-related cost pressure on the gross margin, offsetting improved operating leverage. However, those headwinds should ease in 2027 and 2028, allowing margins to recover and expand, thereby accelerating EPS growth toward the mid-to-high teens range.
This all translates into the excellent outlook below.
Let me note that the main risks to this outlook remain continued disruptions in global trade, particularly between the U.S. and China, and emerging competition as addressed earlier. These risks are accounted for in these projections, but could turn out worse or less impactful.
Alright, that then brings us to valuation, and as so often, this is where I turn less enthusiastic.
Unsurprisingly, a high-quality business such as Intuitive, growing revenue at a consistent mid-teens rate and maintaining enviable margins, rarely comes cheap. The company’s dominance, recurring revenue profile, and long growth runway have long justified a premium multiple, but even that premium has limits.
That said, shares have become noticeably cheaper in recent months, falling around 18% year-to-date and 11% over the past twelve months, driven by concerns about competition and the impact of tariffs and global trade disruptions on its growth momentum, which I honestly deem vastly overblown, especially with Intuitive still performing really well and financial results in the first half showing no weakness.
In the meantime, multiples have come down nicely. At roughly 54× this year’s earnings and 48× next year’s, valuation remains rich in absolute terms, though meaningfully below its five-year average of 61×. The company also trades at a three-year PEG ratio of 3.4, versus a historical average closer to 4.5×, suggesting that while still far from cheap, the stock now sits near the lower end of its long-term valuation range, which is compelling.
At the same time, yes, we are still looking at a 50x earnings multiple, which is rather demanding and still prices in a lot of optimism. Also, Intuitive trades at a substantial premium to peers, even to high-quality names like Stryker, Boston Scientific, and Medtronic, which trade between 20× and 30× forward earnings.
Still, I honestly don’t think these are hard to justify given its excellent outlook, growth runway, brilliant financial health, and market dominance, even if competition increases.
Ultimately, from a valuation perspective, I would say the setup looks fair but not compelling. Intuitive Surgical is one of those companies that is rarely cheap, often expensive, and almost always worth owning.
For long-term investors, the current valuation looks reasonable relative to the quality of the business and the durability of its growth, though not a screaming bargain. I’d call it fairly valued to slightly expensive, a classic case of a top-tier business at a full price. Though I will admit the margin of safety isn’t considerable
For reference, if we take a FY27 exit multiple of 45x, assuming some multiple compression amid growing competition and some moderation in growth, I calculate an end-of-2027 target price of $493. From a current share price of $446, this reflects potential annualized returns of roughly 4%, which is meager.
In other words, given current prices, the potential upside seems limited, and the margin of safety is minimal, even with Intuitive’s history of outperforming consensus estimates.
So, what price makes sense?
I am aiming for a share price closer to $380, which is down another 12% from today’s price, before pulling the trigger. At those levels, the potential upside outweighs the downside risk, and Intuitive becomes a very compelling long-term buy-and-hold.
This is a must-own, but only at the right price.
Rating: Hold - Accumulate below $380
FY27 Target Price: $493
Implied CAGR from the current price: ~4%
Please leave a like if you enjoyed this post and found it valuable!
Thanks a lot for this deep dive !
Well, I see it went up 18% after earnings…don’t think a good entry point will appear anytime soon 🤣